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Abstract
Background: We hypothesized that the addition of dexmedetomidine in a clinically relevant dose to propofol-
remifentanil anesthesia regimen does not exert an adverse effect on motor-evoked potentials (MEP) and
somatosensory-evoked potentials (SSEP) in adult patients undergoing thoracic spinal cord tumor resection.
Methods: Seventy-one adult patients were randomized into three groups. Propofol group (n = 25): propofol-
remifentanil regimenand the dosage was adjusted to maintain the bispectral index (BIS) between 40 and 50.
DP adjusted group (n = 23): Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a
constant infusion of 0.5 μg/kg/h) was added to the propofol-remifentanil regimen and propofol was adjusted
to maintain BIS between 40 and 50. DP unadjusted group (n = 23): Dexmedetomidine (administer as DP
adjusted group) was added to the propofol-remifentanil regimen and propofol was not adjusted. All patients
received MEP, SSEP and BIS monitoring.
Results: There were no significant changes in the amplitude and latency of MEP and SSEP among different groups
(P > 0.05). The estimated propofol plasma concentration in DP adjusted group (2.7 ± 0.3 μg/ml) was significantly lower
than in propofol group (3.1 ± 0.2 μg/ml) and DP unadjusted group (3.1 ± 0.2 μg/ml) (P = 0.000). BIS in DP unadjusted
group (35 ± 5) was significantly lower than in propofol group (44 ± 3) (P = 0.000).
Conclusions: The addition of dexmedetomidine to propofol-remifentanil regimen does not exert an adverse effect on
MEP and SSEP monitoring in adult patients undergoing thoracic spinal cord tumor resection.
Trial registration: The study was registered with the Chinese Clinical Trial Registry on January 31st, 2014.
The reference number was ChiCTR-TRC-14004229.
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Background
Motor-evoked potential (MEP) and somatosensory-evoked
potential (SSEP) monitoring are widely used during
spinal surgeries, which threat the integrity of motor
and sensory pathways in the spinal cord. The effect of
anesthetic agents on the amplitude and latency of MEP
and SSEP monitoring is dose-dependent [1–3]. Total
intravenous anesthesia (TIVA) with propofol and opioid
is commonly recommended for surgeries that require
MEP and SSEP monitoring [1, 4]. However, even pro-
pofol used with a large dose can also affect MEP moni-
toring [5].
Dexmedetomidine is a potent and highly selective
alpha-2 agonist. It has the effect of sedation, analgesia,
sympatholysis, minimal respiratory depression and
possible neuroprotection [6–9]. Its addition to the
anesthetic regimen is believed to have the potential of
sparing other hypnotics requirement, especially propo-
fol, thus facilitating MEP and SSEP monitoring while
providing the beneficial effects it has. Previous studies
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examining the effect of dexmedetomidine on MEP and
SSEP monitoring claimed both a null [4, 10–14] and
significant adverse effect [11, 15]. The design of most
studies was longitudinal in which patients served as
their own controls [10–13]. Therefore, the results may
be confounded by the carryover or top-up effect after
the addition of dexmedetomidine. The only randomized
controlled trial used etomidate instead of propofol for
anesthetic maintenance and this is not a currently recom-
mended practice [4].
Another consideration is that all the previous studies
were done in patients suffering from various non-tumor
spinal conditions. In patients diagnosed with spinal cord
tumor, the combination of dexmedetomidine may affect
MEP and SSEP monitoring differently compared with
surgery on the bony structures only because the neural
pathways may have been adversely injured by the tumor
[16, 17].
In this study we propose our hypothesis that the
combination of dexmedetomidine in a clinically rele-
vant dose to an anesthetic regimen reduces propofol
and remifentanil requirement does not exert an adverse
effect on MEP and SSEP monitoring in patients with
thoracic spinal cord tumors.
Methods
This single-center and randomized study was con-
ducted in Beijing Tiantan Hospital, Capital Medical
University. The study was approved by the Ethics Com-
mittee of Beijing Tiantan Hospital, Capital Medical
University (reference number was ky-2010-018-02).
Written informed consent was obtained from all partici-
pants. The study was registered with the Chinese Clinical
Trial Registry (the reference number was ChiCTR-TRC-
14004229).
Patients
We recruited patients scheduled for elective thoracic
spinal cord tumor resection based on magnetic reson-
ance imaging (MRI) studies. Other inclusion criteria in-
cluded age between 18 and 60 years old and American
Society of Anesthesiologists (ASA) physical status I or II.
The patients who were pregnant and/or lactating,
chronic using or addiction of analgesics were excluded
from the study. The patients who were with illegal drug
or alcohol abuse, obesity (BMI ≥ 30 kg/m2), anemia
(hemoglobin < 11 g/dl), and major organ dysfunctions
were also excluded from the study.
Grouping
Patients who met the recruitment criteria were ran-
domly assigned to one of the three study groups, la-
beled “propofol group”, “DP adjusted group”, or “DP
unadjusted group”. Randomization was based on a
computer generated random digits table (SPSS Inc.,
Chicago, IL). Permuted-block randomization was used
with a block size of 3 and an allocation ratio of 1:1:1.
Since anesthesiologist was in charge of the anesthesia
management and all evaluation of outcomes were based
on the result of electrophysiological monitoring, the
anesthesiologist could not be blinded. Neurophysiolo-
gists and patients were blinded to the study group till
the evaluation finished. In propofol group, the anesthesia
was maintained using propofol and remifentanil infusions
only. The blood plasma concentration of remifentanil was
fixed at 4 ng/ml while the propofol infusion was adjusted
to maintain the BIS measurement between 40 and 50. In
DP adjusted group, dexmedetomidine (0.5 μg/kg loading
dose infused over 10 min followed by a constant infusion
rate of 0.5 μg/kg/h) was added to propofol and remifenta-
nil infusions. While the dexmedetomidine infusion was
standardized and the blood plasma concentration of remi-
fentanil was fixed at 4 ng/ml while the propofol infusion
was adjusted to maintain the BIS measurement between
40 and 50 for 90 % of anesthesia time and no deviations
for more than 5 min. In DP unadjusted group, the
anesthesia was maintained using propofol and remifen-
tanil infusions as in propofol group. After BIS was
maintained between 40 and 50, dexmedetomidine was
then added (0.5 μg/kg loading dose infused over 10 min
followed by a constant infusion rate of 0.5 μg/kg/h).
The propofol was not adjusted as in DP unadjusted
group.
Anesthesia and management
The patients did not receive premedication. Anesthesia
was induced by propofol (5 μg/ml) infusion managed
with a Diprifusor propofol infusion device (Marsh model,
Master Target Control infusion system, Fresenius-Vial,
Brezins, France), remifentanil (4 ng/ml) infusion managed
with an infusion device (Minto model CP-600TCI, Beijing
Slgo Medical Technology Co., Ltd., Beijing, China) and
rocuronium (0.6 mg/kg). Then patients received endo-
tracheal intubation and mechanical ventilation adjusting
to maintain the end-tidal carbon dioxide between 35 and
40 mmHg. In addition to the routine ASA monitors, pa-
tients received MEP (Cascade, Cadwell Laboratories Inc,
WA, USA), SSEP (Cascade, Cadwell Laboratories Inc,
WA, USA), bispectral index (BIS) (BIS™, Covidien, San
Jose, CA, USA) and intra-arterial blood pressure monitor-
ing. Bradycardia, defined as the heart rate (HR) < 50 bpm,
was treated with atropine (0.5 mg) bolus administration.
Hypotension, defined as a decreasing of mean arterial
pressure (MAP) more than twenty percentage of the base-
line, was treated by using a dopamine infusion titrated.
The baseline blood pressure value was determined based
on preoperative evaluation on the day before surgery.
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Motor- and somatosensory-evoked potential monitoring
MEP was recorded from paired needle electrodes
placed bilaterally in the tibias anterior and extensor
digital muscles, and hand muscles. Electrical current
delivered to corkscrew electrodes were inserted at the
C3 and C4 sites (international 10–20 system) with
train of six to nine pulses, 300 to 500 volts, 75 ms
interval pause (ISI) and one to four microsecond of
inter-stimulus interval using Cadwell Cascade neuro-
physiologic monitoring system (Cascade, Cadwell
Laboratories Inc, WA, USA). Anodal stimulation was
applied to trigger contralateral MEP responses. The
number of pulses and voltage were established at base-
line and maintained throughout the surgery. Surface-
stimulating electrodes for SSEP monitoring were placed
over each ulnar nerve at the wrists and over each posterior
tibial nerve at the ankles. Needle electrodes were placed
over the somatosensory hand cortex at scalp sites C3′-Fz,
C4′-Fz, Cz′-Fz and C3′-C4′ to record the primary cor-
tical responses. Ulnar and posterior tibial nerves were
stimulated synchronously at 2.79/s and averaged over
500 stimuli. Ulnar nerves were stimulated at 15 mA,
and posterior tibial nerves were stimulated at 25 mA.
Then europhysiologists were blinded to the group till
the evaluation finished.
Fig. 1 Flow chart of study protocol
Fig. 2 Flow chart of patient selection









Propofol group (n = 25) 18/7 40 ± 11 169 ± 7 68 ± 11
DP adjusted group
(n = 23)
12/11 40 ± 14 164 ± 7 65 ± 10
DP unadjusted group
(n = 23)
13/10 41 ± 13 166 ± 9 63 ± 13
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Prior to surgery, the muscle strength of the left and
right lower extremity was assessed by the attending
neurosurgeon who was blinded to the randomization
using a 0-2-5 scale, with 5 indicating normal strength
and 0 complete paralysis. MEP, SSEP, BIS, mean arter-
ial pressure (MAP) and heart rate (HR) were measured
at 4 different time points (Fig. 1). T1 was the baseline
value obtained 30 min after anesthesia induction and
endotracheal intubation but before the dexmedetomidine
infusion. T2 was 10 min after T1 when the dexmedetomi-
dine loading dose infusion (0.5 μg/kg over 10 min) was
just finished in DP adjusted group and DP unadjusted
group. All variables were recorded again when the dexme-
detomidine maintenance infusion (0.5 μg/kg/h) has lasted
for 10 (T3) and 20 (T4) minutes, respectively, in both
groups. The muscle relaxation related to rocuronium was
reversed using neostigmine (0.05–0.07 mg/kg) if necessary
before the first measurement. A T4/T1 90 % recovery of
the muscle strength based on the train-of-four ratio was
deemed acceptable for the study. All measurements were
done with the patient in the lateral position and prior to
skin incision in order to avoid the confounding effect of
surgical manipulation on MEP and SSEP monitoring.
More than 50 % decrease of the amplitude and more than
10 % prolongation of the latency of both SSEP and MEP
monitoring from the baseline values were defined as clin-
ically meaningful changes [18].
Statistical analysis
Sample size calculation was performed by PASS 2008
software (NCSS LLC, USA) for windows. Based on the
study in which used MEP amplitude (500 μV; SD,110) to
detect a 50 % difference in MEP amplitude (decrease
from 500 to 250 μV) [13], 20 patients were required to
detect an effect size of 0.8, assuming a power of 80 %
and a 2-sided α level of 5 %. Considering the possibility
of early termination during the study and 20–30 % for a
drop-out rate, therefore 30 patients were recruited in
each group.
Statistical analyses were performed using the Statis-
tical Package for Social Sciences (Version 19.0, SPSS
Inc., Chicago, IL). All quantitative data were analyzed
for normal distribution and homogeneity of variance.
Data that showed a normal distribution were presented
as the means ± SD. The non-normal distribution data
were presented as median. One-way analysis of variance
(ANOVA) of repeated measurements was used to evaluate
differences between the means at different time points in
one group. Variables between groups underwent Student-
Newman-Keuls tests with multiple comparison correction.
All P values were two sided, and α level of 0.05 was con-
sidered statistically significant.
Results
Ninety patients were equally enrolled in this study. 19
patients were excluded from analysis due to either poor
quality MEP monitoring (3, 5, 5 in 3 groups respect-
ively) or failure to regain T4 ratio which defined as T4/
T1 recovered less than 90 % based on the train-of-four
ratio after the intubation (2 in each group). The pa-
tients’ recruitment was showed in Fig. 2. There were no
significant differences of age, gender, height, and weight
among groups (Table 1). There were no significant dif-
ferences in the muscle strength of the left and right
lower extremities among different groups (Table 2).
The estimated blood plasma concentration of propofol
in DP adjusted group (2.7 ± 0.3 μg/ml) was significantly
lower than in propofol group and DP unadjusted group
(3.1 ± 0.2 μg/ml and 3.1 ± 0.2 μg/ml) (P = 0.000) (Table 3).
There were no significant differences in MAP and HR
among different measurement points in propofol group
(Table 4). In DP adjusted group (93 ± 14 mmHg) and DP
unadjusted group (94 ± 10 mmHg) the MAP was signifi-
cantly higher than propofol group (86 ± 15 mmHg) (P =
0.037, 0.032). In DP unadjusted group, the HR at T2-T4
(59 ± 6, 59 ± 5, 60 ± 6pbm) was lower than T1 (66 ± 8pbm)
(P = 0.000, 0.000, 0.003, respectively).
There were no significant differences in the BIS of propo-
fol groups and DP adjusted group (Table 4). However, the
BIS measured at points T2-T4 in DP unadjusted group (37
± 6, 35 ± 5, 35 ± 6) was lowered than the corresponding
points in propofol group (44 ± 3, 44 ± 3, 42 ± 8) (P = 0.000).
Table 2 Muscle strength of the lower extremities before
surgery (mean ± SD)
Group Left P Right P
Propofol group (n = 25) 4.3 ± 1.0 4.2 ± 1.0
DP adjusted group (n = 23) 4.1 ± 1.1 0.72 4.1 ± 1.1 0.82
DP unadjusted group (n = 23) 4.2 ± 1.1 0.83 4.3 ± 1.1 0.74
P: Comparison with propofol group
Table 3 Estimated plasma concentration of propofol (μg/ml, mean ± SD) at different time points
Group T1(μg/ml) P T2(μg/ml) P T3(μg/ml) P T4(μg/ml) P
Propofol group (n = 25) 3.1 ± 0.2 3.1 ± 0.2 3.1 ± 0.2 3.1 ± 0.2
DP adjusted group (n = 23) 3.0 ± 0.2 0.313 2.8 ± 0.2a 0.003 2.7 ± 0.3*a 0.000 2.7 ± 0.3*a 0.000
DP unadjusted group (n = 23) 3.1 ± 0.2 0.829 3.1 ± 0.2 0.829 3.1 ± 0.2 0.939 3.1 ± 0.2 0.939
* P = 0.01 (comparison among different time points)
aComparison with propofol group
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There were no significant changes in the amplitude
and latency of both MEP (Table 5) and SSEP (Table 6)
among different time pointsin all 3 groups (P > 0.05).
There were also no significant differences of the mea-
surements among different groups (P > 0.05).
Discussion
This randomized controlled study in patients with
thoracic spinal cord tumors shows that the addition of
dexmedetomidine to a TIVA regimen comprising of
propofol and remifentanil does not adversely affect the
Table 4 MAP, HR, BIS at different time points (mean ± SD)
Variable Group T1 P T2 P T3 P T4 P
MAP (mmHg) Propofol group (n = 25) 86 ± 11 86 ± 15 86 ± 13 84 ± 12
DP adjusted group (n = 23) 80 ± 11 0.061 93 ± 14**a 0.037 95 ± 15**a 0.019 95 ± 12**a 0.003
DP unadjusted group (n = 23) 80 ± 10 0.098 94 ± 10**a 0.032 95 ± 13**a 0.019 95 ± 11**a 0.003
HR (bpm) Propofol group (n = 25) 65 ± 10 60 ± 7 59 ± 6 60 ± 8
DP adjusted group (n = 23) 64 ± 10 0.541 59 ± 9 0.464 58 ± 9* 0.816 59 ± 8 0.626
DP unadjusted group (n = 23) 66 ± 8 0.841 59 ± 6** 0.489 59 ± 5** 0.842 60 ± 6* 0.850
BIS Propofol group (n = 25) 45 ± 3 44 ± 3 44 ± 3 42 ± 8
DP adjusted group (n = 23) 44 ± 4 0.393 43 ± 3 0.146 43 ± 3 0.428 43 ± 3 0.534
DP unadjusted group (n = 23) 45 ± 3 0.732 37 ± 6**a 0.000 35 ± 5**a 0.000 35 ± 6**a 0.000
*P < 0.05, **P = 0.000 (comparison among different time points)
aComparison with propofol group
Table 5 Motor-evoked potential at different time points (mean ± SD)
Group Measurement T1 T2 T3 T4
Propofol group (n = 25) ULA (uv) 280 ± 148 307 ± 147 326 ± 154 326 ± 169
ULL (ms) 20.7 ± 3.2 21.3 ± 2.2 21.6 ± 2.4 21.9 ± 2.3
URA (uv) 323 ± 139 307 ± 138 366 ± 164 343 ± 145
URL (ms) 21.2 ± 3.6 22.2 ± 4.0 21.8 ± 2.7 21.6 ± 3.5
LLA (uv) 152 ± 84 177 ± 82 208 ± 141 221 ± 113
LLL (ms) 38.9 ± 4.8 40.1 ± 5.7 40.2 ± 6.9 39.4 ± 6.6
LRA (uv) 127 ± 91 121 ± 84 140 ± 90 131 ± 105
LRL (ms) 39.0 ± 9.9 39.4 ± 10.6 40.4 ± 11.1 39.6 ± 4.2
DP adjusted group (n = 23) ULA (uv) 293 ± 131 341 ± 207 313 ± 155 313 ± 178
ULL (ms) 20.8 ± 2.1 21.8 ± 3.6 21.3 ± 3.6 20.9 ± 2.8
URA (uv) 256 ± 137 302 ± 193 303 ± 158 339 ± 206
URL (ms) 21.1 ± 2.6 20.6 ± 2.8 20.9 ± 3.0 21.5 ± 3.3
LLA (uv) 174 ± 135 185 ± 129 179 ± 106 153 ± 78
LLL (ms) 39.4 ± 5.2 39.5 ± 3.6 39.2 ± 3.2 37.3 ± 9.9
LRA (uv) 154 ± 77 173 ± 153 187 ± 137 160 ± 98
LRL (ms) 40.5 ± 3.9 40.6 ± 4.1 40.8 ± 5.0 41.3 ± 5.3
DP unadjusted group (n = 23) ULA (uv) 354 ± 179 353 ± 116 343 ± 153 355 ± 158
ULL (ms) 21.4 ± 2.3 21.3 ± 2.4 22.1 ± 4.0 23.1 ± 3.8
URA (uv) 354 ± 161 351 ± 191 316 ± 197 292 ± 163
URL (ms) 21.6 ± 2.6 21.7 ± 3.0 22.4 ± 4.0 23.1 ± 4.1
LLA (uv) 171 ± 114 196 ± 171 215 ± 178 169 ± 144
LLL (ms) 41.2 ± 4.4 40.0 ± 4.2 39.8 ± 3.5 39.9 ± 3.6
LRA (uv) 206 ± 153 207 ± 192 225 ± 177 199 ± 138
LRL (ms) 38.4 ± 10.7 39.8 ± 4.2 40.7 ± 4.7 38.2 ± 10.0
ULA amplitude of left upper limb, ULL latency of left upper limb, URA amplitude of right upper limb, URL latency of right upper limb, LLA amplitude of left lower
limb, LLL latency of left lower limb, LRA amplitude of right lower limb, LRL latency of right lower limb
P: Comparison with propofol group
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MEP and SSEP monitoring, and the addition of dexme-
detomidine reduces the propofol requirements for a
comparable BIS measurement. Moreover, the deepen-
ing of anesthesia via propofol infusion does not neces-
sarily affect the MEP and SSEP monitoring.
All major hypnotic agents used in anesthesia can exert
dose-dependent adverse effect on MEP and SSEP moni-
toring [1–3]. Inhalational anesthetic agents have a potent
effect and therefore are either avoided or used in low
concentrations during MEP monitoring [1–4]. Propofol
at higher concentrations can also depress the amplitude
of the MEP [5]. Currently, the anesthetic technique that
is frequently recommended during MEP and SSEP
monitoring is a TIVA regimen comprising of multiple
drugs at lower doses than usually used. The rationale of
this strategy is to provide an adequate and balanced
anesthesia via a combination of drugs that have differ-
ent but supplementary mechanisms while minimizing
the adverse effect on evoked potential monitoring of an
otherwise large dose if the drug is used alone. This
strategy is typically executed via a propofol-opioid, ei-
ther remifentanil or fentanyl, combination [1, 4].
The multiple advantageous properties of dexmedeto-
midine make it a potentially useful drug for inclusion in
a TIVA regimen in monitored cases [11–14]. The ration-
ale for adding dexmedetomidine is to reduce the dose of
propofol or to deepen the anesthesia without increasing
the propofol infusion rate, in addition to potentiation of
the opioid analgesia [11–14]. Previous studies suggested
that the effect of dexmedetomidine on MEP and SSEP
monitoring is dose-dependent with the drug blood con-
centration of 0.3–0.6 ng/ml producing no adverse effect
[10] while that of 0.6–0.8 ng/ml causing a significant at-
tenuation of the MEP amplitude [11]. However, these re-
sults are difficult to consolidate because one study used
propofol-remifentanil [12] while the other desflurane-
remifentanil [10]. Moreover, the designs of these studies
were heterogeneous including drug titration and patient
Table 6 Somatosensory-evoked potential at different time points (mean ± SD)
Group Measurement T1 T2 T3 T4
Propofol group (n = 25) ULA (uv) 2.0 ± 0.9 1.9 ± 0.7 1.8 ± 0.9 2.1 ± 1.0
ULL (ms) 20.1 ± 0.8 20.3 ± 1.2 20.5 ± 1.4 20.6 ± 1.5
URA (uv) 2.4 ± 1.4 2.1 ± 1.1 2.3 ± 1.3 1.9 ± 1.1
URL (ms) 20.2 ± 1.4 20.2 ± 1.3 20.5 ± 1.3 20.6 ± 1.6
LLA(uv) 1.1 ± 1.1 1.0 ± 0.9 1.1 ± 0.8 1.1 ± 0.9
LLL (ms) 39.6 ± 4.0 40.1 ± 4.2 40.2 ± 4.3 39.8 ± 4.6
LRA(uv) 1.3 ± 1.2 1.6 ± 2.2 1.0 ± 1.0 0.8 ± 0.9
LRL (ms) 40.8 ± 4.6 40.7 ± 4.5 40.9 ± 4.5 40.7 ± 4.7
DP adjusted group (n = 23) ULA (uv) 2.0 ± 1.1 2.1 ± 1.1 2.0 ± 1.1 2.0 ± 1.1
ULL (ms) 19.2 ± 1.5 19.4 ± 1.6 19.7 ± 1.6 19.7 ± 1.7
URA (uv) 2.1 ± 1.4 2.1 ± 1.3 2.3 ± 1.2 2.3 ± 1.3
URL (ms) 19.8 ± 1.8 19.8 ± 1.5 20.0 ± 1.5 19.9 ± 1.5
LLA(uv) 1.5 ± 1.5 1.5 ± 1.6 1.8 ± 2.0 1.5 ± 1.2
LLL(ms) 39.7 ± 4.4 40.4 ± 4.1 40.9 ± 4.8 41.2 ± 4.1
LRA(uv) 1.4 ± 1.6 1.6 ± 1.8 1.6 ± 2.0 1.5 ± 1.8
LRL (ms) 38.8 ± 3.8 40.0 ± 3.3 40.1 ± 3.2 39.6 ± 2.4
DP unadjusted group (n = 23) ULA (uv) 1.6 ± 1.0 1.7 ± 1.0 1.7 ± 1.1 1.8 ± 1.1
ULL (ms) 19.2 ± 2.1 19.4 ± 2.2 19.6 ± 2.4 19.2 ± 3.1
URA(uv) 1.6 ± 1.0 1.7 ± 0.9 1.5 ± 0.9 1.6 ± 0.8
URL(ms) 19.8 ± 2.7 20.1 ± 2.6 20.3 ± 2.3 20.1 ± 2.7
LLA(uv) 1.1 ± 1.0 0.9 ± 0.7 1.2 ± 1.0 1.3 ± 1.0
LLL(ms) 39.8 ± 4.3 39.9 ± 3.9 40.6 ± 4.1 41.0 ± 4.3
LRA(uv) 1.0 ± 0.7 0.7 ± 0.4 1.1 ± 0.7 1.3 ± 1.0
LRL (ms) 39.8 ± 4.1 40.2 ± 4.1 41.3 ± 4.5 41.1 ± 4.3
ULA amplitude of left upper limb, ULL latency of left upper limb, URA amplitude of right upper limb, URL latency of right upper limb, LLA amplitude of left lower
limb, LLL latency of left lower limb, LRA amplitude of right lower limb, LRL latency of right lower limb
P: comparison with propofol group
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populations. The major difference between our study
and previously study is that we used arandomized con-
trolled study. Our results show that the addition of
dexmedetomidine to a TIVA regimen does not ad-
versely affect the MEP and SSEP monitoring. In con-
trast, Mahmoud et al. reported two cases of loss of
MEP amplitude during pediatric spine surgery with
dexmedetomidine [15]. One case was an obese child,
propofol and dexmedetomidine were calculated on ac-
tual rather than lean body mass. It is therefore pos-
sible that the patient had higher serum concentration
of both drugs. In the second patient, decreased MEP
amplitude was monitored after a bolus of 1 μg/kg dex-
medetomidine was administered over 10 min. It is
possible that the combination of dexmedetomidine
and propofol might have a cumulative suppressing ef-
fect on MEP. Our study included patients between 18
and 60 years old and the dose of dexmedetomidine we
use that would approximate the plasma levels achieved
by Bala et al. [10]. Even in DP unadjusted group, the
deepening of anesthesia via propofol infusion does not
necessarily affect the MEP and SSEP monitoring.
This study has limitations. First, a fixed dose of dex-
medetomidine, which is 0.5 μg/kg loading dose for
10 min followed by a 0.5 μg/kg/h infusion, didn’t
ensure a constant level of its plasma concentration.
Second, we recruited patients scheduled for elective
thoracic spinal cord tumor resection. Poor signal of
MEP and SSEP is inavoidable in such patients. Malhotra
[16] reported that ability to achieve intraoperative monitor
baseline data varied from 70 to 98 % for SSEP and 66 to
100 % for MEP in absence of neural axis abnormality. In
this study, the total excluded number in three groups are
respectively 5/30, 7/30, 7/30 respectively. Although the
high percent of failure rate may lead to a selection bias,
the remaining patients in each group are still comparable
to study the effects of dexmedetomidine in a clinically
relevant dose on MEP and SSEP.
Conclusion
The addition of dexmedetomidine in a commonly used
clinical dose to a propofol-remifentanil regimen does not
exert an adverse effect on MEP and SSEP monitoring in
adult patients undergoing thoracic spinal cord tumor re-
section. In this patient population, dexmedetomidine
could be added to the TIVA regimen without altering the
propofol dose thereby deepening the anesthesia without
adversely influencing MEP and SSEP monitoring.
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